Adult patients aged 18 years and older:
Pediatric patients aged 12 to 17 years:
Review what your patients should know about treatment with ARCALYST.See The Details
ARCALYST® (rilonacept), an interleukin-1 blocker, is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children age 12 and over. It has not been studied in patients with Neonatal-Onset Multisystem Inflammatory Disease (NOMID).
Please see the full Prescribing Information for ARCALYST.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.
IL-1 blockade may interfere with immune response to infections. Serious, life-threatening infections have been reported in patients taking ARCALYST. ARCALYST should be discontinued if a patient develops a serious infection. Taking ARCALYST with TNF inhibitors is not recommended because this may increase the risk of serious infections.